Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncol Rep
Hoofdauteurs: OKITA, RIKI, SHIMIZU, KATSUHIKO, NOJIMA, YUJI, YUKAWA, TAKURO, MAEDA, AI, SAISHO, SHINSUKE, NAKATA, MASAO
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: D.A. Spandidos 2015
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://ncbi.nlm.nih.gov/pubmed/26503698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4314
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items